Ramipril Dosing and Monitoring in Specific Clinical Situations

Post‑Myocardial Infarction Heart Failure

The ACC/AHA guideline recommends initiating ramipril at 2.5 mg twice daily and titrating to 5 mg twice daily as tolerated in patients with anterior infarction, left‑ventricular systolic dysfunction (ejection fraction ≤ 0.40), or heart failure. 1
For post‑MI heart failure, start at 2.5 mg twice daily (or 1.25 mg twice daily if the patient is hypotensive) and aim for a target dose of 5 mg twice daily; dose can be increased after one week of the starting dose and subsequently roughly every three weeks, provided the patient remains hemodynamically stable. 1
After the first ramipril dose in this setting, patients should be observed under medical supervision for at least 2 hours, and blood pressure must remain stable for an additional hour before discharge. 1

In adults whose creatinine clearance is ≤ 40 mL/min, begin ramipril at 1.25 mg once daily and titrate upward as needed, not exceeding a maximum total daily dose of 5 mg. 2

Renal function and serum potassium should be measured within 1–2 weeks of starting ramipril, after each dose increase, and at least annually in older patients on ACE‑inhibitors. [3][4]5
Older adults have a greater susceptibility to ACE‑inhibitor‑related reductions in renal function, underscoring the need for vigilant monitoring. [3][4]5

Moderate‑dose ACE‑inhibitor therapy, including ramipril, is significantly associated with the development of hyperkalemia in older patients. [3][4]5
Concomitant use of potassium supplements, potassium‑salt substitutes, or potassium‑sparing diuretics with ramipril should be avoided or closely monitored because of the heightened hyperkalemia risk. [3][4]5